Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University Hospital Southampton NHS Foundation Trust
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01334060CT.gov WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| P.Dom-Wt1-126 Dna Vaccine (this asset) | University Hospital Southampton NHS Foundation Trust | P2 | B · 57 |
| Cyclophosphamide | Roswell Park Cancer Institute | P4 | BB |
| Busulfanum | University of Rochester | P4 | B |
| P.Dom-Wt1-37 Dna Vaccine | University Hospital Southampton NHS Foundation Trust | P2 | B |
| Alemtuzumab | Steven E. Coutre | P2 | B |
| Fludarabine | Roswell Park Cancer Institute | P2 | B |
| Tocilizumab | Medical College of Wisconsin | P1 | CC |
| Nivolumab | Medical College of Wisconsin | P1 | CC |
| Avn-944 | Vertex Pharmaceuticals Incorporated | P1 | CC |
+4 more in the Chronic Leukemia cohort
Other indications for P.Dom-Wt1-126 Dna Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Leukemia | — | P2 | B · 57 |
| Acute Myeloid Leukemia | — | P2 | B · 57 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. P.Dom-Wt1-126 Dna Vaccine in Chronic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pdom-wt1-126-dna-vaccine-chronic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →